Schizophrenia is formally classified as a mental disorder in which a person has “lost touch with reality”. Some of the symptoms of schizophrenia are categorized as hallucinatory phenomena (both audio and visual), delusions, and unusual ways of thinking. It’s considered to be an illness that is debilitating to the person as it hampers their ability to live a “normal” life.

A 2005 review in the journal Medical Hypothesis presents the history of endogenous DMT research and the proposed link between the molecule and mental disturbances including schizophrenia. A few studies in the 1970s observed greater urinary excretion of DMT amongst schizophrenic patients compared to controls. However, follow up studies found inconsistencies in this transpiration and the DMT-schizophrenia link has largely been discarded in favor of the “dopamine hypothesis”.

While much of the focus as it pertains to endogenous DMT is about measuring levels of the specific compound, it seems as though measuring the levels of monoamine oxidase (MAO) activity would provide an additional layer of insight. Monoamine oxidase is the enzyme that deaminates DMT leading to it’s breakdown and subsequent drop in measurable levels. As many of you know… the shamanic brew known as Ayahuasca contains a monoamine oxidase inhibitor (MAOI) alongside DMT in order to prevent the rapid breakdown of the psychedelic. This leads to the prolonged effects of Ayahuasca compared to inhalation or injection of DMT.

As we’ve cited in the past, a 2001 study published in the journal Life Sciences showcased the effects of increased hydroxyl radical (•OH) generation and suppression of both MAO-A and MAO-B activity. The outcome was as follows: “Results showed that the generation of •OH (hydroxyl radical) significantly reduced both MAO-A (85–53%) and MAO-B (77–39%) activities, exhibiting a linear correlation between both MAO-A and MAO-B activities and the amount of •OH produced. The reported inhibition was found to be irreversible for both MAO-A and MAO-B. Assuming the proven contribution of MAO activity to brain oxidative stress, this inhibition appears to reduce this contribution when an overproduction of •OH occurs.”

In 2011, the International Journal of Molecular Sciences published a study comparing the levels of •OH radicals of schizophrenic patients versus normal volunteers. The results found that “concentrations of •OH radicals in serum blood of healthy patients are considerably lower than in serum blood of people with pathological schizophrenia”.

This data would seem to potentially revive the discussion of DMT as it pertains to schizophrenia. Suppression of monoamine oxidase activity via elevation of hydroxyl radical formation would lead to less breakdown of endogenous DMT potentially coinciding with “hallucinatory” phenomena. While we believe that there are many biochemical abnormalities relating to the symptomatology of “mental illness” outside of strictly DMT… the question is whether the DMT/monoamine oxidase activity abnormalities in schizophrenic patients is the cause or effect of the illness?

A 2016 fMRI study in the journal Psychological Medicine observed that the brains of schizophrenic patients have the ability to reorganize and regenerate. This goes against previous beliefs that brain degradation progresses linearly with no inherent repair mechanisms.

These findings indicate that the upregulation of the combination of endogenous DMT(s) and MAOI’s might play key underlying factors in the regenerative capabilities of the schizophrenic brain in addition to causing some of the “hallucinatory” phenomena.

A recent 2017 study published in Molecular Psychiatry found that whole brain connectivity was detrimentally affected in schizophrenics. The two brain areas found to be affected the most were the corpus callosum (the structure that enables the two hemispheres to communicate with one another) and the frontal part of the corona radiata (a brain region key for processing information).

This information would allude to the fact that inherent repair mechanisms exist in an attempt to combat the decreased connectivity by releasing chemical compounds that attempt to stimulate activity that leads to increased connectivity. If increased levels of DMT(s) and suppressed MAO activity coincide with greater neurogenesis and subsequent connectivity, it doesn’t make sense that these factors play a role in the neurological atrophy that coincides with mental illness.

As we touched upon in the first part of the “Gamma Wave” series, “Aha!” moments correlate with gamma waves indicating the binding of a set of neurons for the first time. This action creates a new neural pathway coinciding with greater levels of brain connectivity. In 2010, the Harvard Review of Psychiatry would publish a review of EEG data pertaining to schizophrenics finding a deficit in gamma wave amplitude. Interestingly enough, a 2015 study in JAMA Psychiatry found that spontaneous increases in gamma wave coincided with auditory hallucinations in schizophrenics. We believe that there is a definite gamma wave-DMT relationship and in schizophrenics, regional surges in DMT coincide with an attempt to retain connectivity in a degrading environment.

We presume that DMT/Endohuasca is not the cause of schizophrenia but rather part of the complex repair mechanisms utilized by the body in an attempt to ameliorate the situation. Perhaps some of the inconclusive data in decades past regarding DMT excretion and mental illness have to do with certain patients exuding some characteristics of mental illness while not actually having the anatomical degradation associated with mental illness.

There lies the possibility that people with hyper-connected brains (such as Albert Einstein) perceive the world differently from others. Symptomatology of schizophrenia such as hearing voices, having “visions”, employing unusual thought-process methodology, and an overall disengagement of societal norms could also be found in “gifted” individuals. Many a luminary throughout history have been labeled as “crazy” at one point or another in their lifetimes. Having futuristic insights and being dissatisfied with the current status quo is hardly a reason to diagnose someone as schizophrenic. It’s important to note that without fMRI brain connectivity imaging, medical diagnosis for mental illness can be a very inexact science and utilizing “labels” does little to understand people as individuals.

In conclusion… do we believe that DMT is involved in generating some of the symptoms of schizophrenia?

Absolutely.

Do we believe that DMT is the cause of the deterioration of the brain and the subsequent diagnosis of schizophrenia?

Absolutely not.

Do we understand why the body couldn’t just repair itself without the “hallucinatory” phenomena?

No.

Do we understand hallucinatory phenomena within itself?

Not really.

The body is a complex symphony of chemical and electrical processes. The incessant quest for reductionism as it pertains to physiology is a silly endeavor that only leads to more confusion based on unnecessary unconnected discourse. It’s been noted that basic, therapeutic models involving sleep, nutrition, music, meditation, and yoga have all induced positive effects on schizophrenic patients. By contrast… environments of high stress, low quality nutrition, and insufficient sleep have all been observed to exacerbate symptoms of the disease. It would seem logical that a combination of practices that lead to optimization of one’s own basic physiology would create the necessary environment to repair damaged connectivity within the brain.

Indolethylamine N-methyltransferase (INMT) is an enzyme found in the lungs (thyroid & adrenals as well) that has been identified as being a key compound in converting Tryptamine into DMT(s). Elevated levels of INMT in schizophrenics would provide additional support for the DMT-schizophrenia theory. A 1972 study in the journal Life Sciences was published comparing the blood levels of INMT of schizophrenic volunteers (acute and chronic) versus normal controls. The results were as follows: N-methyltraneferase activity is not detectable in normal controls, but is present at detectable levels in both chronic and acute schizophrenics.

*A 2010 study published in Neuro Endocrinology Letters measured bufotenin (5-HO-DMT) levels in the urine of patients with schizophrenia and autism compared to control volunteers. It was observed that the urine of schizophrenic subjects contained nearly 300% more bufotenin than the controls. This is an interesting and important study as it utilizes a more modern assay/equipment than what was utilized in the 1970’s albeit the sample size was relatively small.

(There are numerous studies showcasing a definitive relationship between suppressed monoamine oxidase activity and schizophrenia. However, most of the studies pertain directly to MAO-B suppression in the platelets rather than MAO-A (There are 2 types of monoamine oxidases in the body). Nevertheless, it seems as though suppression or distinct changes in MAO-A activity is potentially taking place as it coincides with the dopamine hypothesis (excessive activity of certain dopaminergic circuits) of schizophrenia. Numerous studies have showcased genetic changes in MAO-A within schizophrenics. This could allude to the notion that the deamination process could be altered affecting the rate in which DMT is broken down. Wild speculations indeed…)

If you appreciate the research that goes into these writings you can tip us at the Q4LT Patreon page. Thank you very much in advance!